MX355729B - Formulacion en polvo seco que comprende un corticoesteroide y un beta-adrenergico para administracion por inhalacion. - Google Patents

Formulacion en polvo seco que comprende un corticoesteroide y un beta-adrenergico para administracion por inhalacion.

Info

Publication number
MX355729B
MX355729B MX2014008631A MX2014008631A MX355729B MX 355729 B MX355729 B MX 355729B MX 2014008631 A MX2014008631 A MX 2014008631A MX 2014008631 A MX2014008631 A MX 2014008631A MX 355729 B MX355729 B MX 355729B
Authority
MX
Mexico
Prior art keywords
corticosteroid
dry powder
adrenergic
inhalation
beta
Prior art date
Application number
MX2014008631A
Other languages
English (en)
Other versions
MX2014008631A (es
Inventor
Monari Elisa
Maria Cantarelli Anna
Cocconi Daniela
Pasquali Irene
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355729(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2014008631A publication Critical patent/MX2014008631A/es
Publication of MX355729B publication Critical patent/MX355729B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación en polvo seco que comprende corticoesteroide y un fármaco adrenérgico beta2 en combinación, su proceso de preparación, y usos terapéuticos de la misma.
MX2014008631A 2012-01-25 2013-01-23 Formulacion en polvo seco que comprende un corticoesteroide y un beta-adrenergico para administracion por inhalacion. MX355729B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152392 2012-01-25
PCT/EP2013/051187 WO2013110632A1 (en) 2012-01-25 2013-01-23 Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation

Publications (2)

Publication Number Publication Date
MX2014008631A MX2014008631A (es) 2014-08-21
MX355729B true MX355729B (es) 2018-04-27

Family

ID=47715987

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001311A MX368199B (es) 2012-01-25 2013-01-23 Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación.
MX2014008631A MX355729B (es) 2012-01-25 2013-01-23 Formulacion en polvo seco que comprende un corticoesteroide y un beta-adrenergico para administracion por inhalacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016001311A MX368199B (es) 2012-01-25 2013-01-23 Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación.

Country Status (38)

Country Link
US (3) US10028964B2 (es)
EP (7) EP3527196B1 (es)
JP (1) JP6104282B2 (es)
KR (3) KR101560288B1 (es)
CN (2) CN104080444B (es)
AR (1) AR089805A1 (es)
AU (1) AU2013211656B2 (es)
BR (1) BR112014017481A8 (es)
CA (1) CA2862548C (es)
CL (1) CL2014001966A1 (es)
CO (1) CO7010836A2 (es)
CY (1) CY1120684T1 (es)
DK (5) DK2806855T3 (es)
EA (2) EA031566B1 (es)
ES (5) ES2683254T3 (es)
FI (1) FI3412277T3 (es)
GE (1) GEP201706767B (es)
HK (1) HK1200021A1 (es)
HR (5) HRP20221432T1 (es)
HU (5) HUE040525T2 (es)
IL (1) IL233784A0 (es)
LT (5) LT2806855T (es)
MA (1) MA35859B1 (es)
MX (2) MX368199B (es)
MY (1) MY165888A (es)
NZ (1) NZ627837A (es)
PE (1) PE20141703A1 (es)
PH (1) PH12014501565B1 (es)
PL (5) PL3527197T3 (es)
PT (5) PT3412277T (es)
RS (5) RS63759B1 (es)
SG (1) SG11201404350PA (es)
SI (2) SI2806855T1 (es)
TN (1) TN2014000322A1 (es)
TW (1) TWI559940B (es)
UA (1) UA115543C2 (es)
WO (1) WO2013110632A1 (es)
ZA (1) ZA201405464B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2683254T3 (es) * 2012-01-25 2018-09-25 Chiesi Farmaceutici S.P.A. Formulación en polvo seca que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación
ES2867552T3 (es) 2013-07-11 2021-10-20 Chiesi Farm Spa Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación
UA118861C2 (uk) * 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій
US10517828B2 (en) 2014-10-08 2019-12-31 Zambon S.P.A. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
WO2018059390A1 (zh) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 药物组合物
MX2019012931A (es) * 2017-05-11 2020-01-20 Chiesi Farm Spa Proceso para preparar una formulacion de polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico.
EP3687500A1 (en) * 2017-09-29 2020-08-05 Crititech, Inc. Glucocorticoid particles and their use
EP3910324A1 (en) * 2018-08-07 2021-11-17 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
MA54045A (fr) 2018-10-30 2021-09-08 Chiesi Farm Spa Appareil pour administrer des médicaments à des patients ventilés mécaniquement
KR20220066906A (ko) 2019-09-24 2022-05-24 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말 제제를 위한 신규 담체 입자
MX2023001875A (es) 2020-08-14 2023-06-29 Norton Waterford Ltd Formulación inhalable de propionato de fluticasona y sulfato de albuterol.
CN118414147A (zh) * 2021-12-21 2024-07-30 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
CZ303154B6 (cs) * 1998-11-13 2012-05-09 Jagotec Ag Suchá prášková formulace k inhalaci obsahující stearát horecnatý
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
ES2359576T5 (es) 2002-07-31 2020-03-03 Chiesi Farm Spa Inhalador de polvo
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB0914240D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Steroid solvates
BR112012007484A2 (pt) * 2009-10-02 2020-06-09 Chiesi Farm Spa formulações aerossóis farmacêuticas de formoterol e dipropionato de beclometasona
TR201811349T4 (tr) * 2010-04-01 2018-09-21 Chiesi Farm Spa İnhalasyon i̇çi̇n kuru toz taşiyici parti̇külleri̇n hazirlanmasi i̇çi̇n proses.
NO2560611T3 (es) 2010-04-21 2018-06-02
ES2683254T3 (es) * 2012-01-25 2018-09-25 Chiesi Farmaceutici S.P.A. Formulación en polvo seca que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación
ES2867552T3 (es) * 2013-07-11 2021-10-20 Chiesi Farm Spa Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación

Also Published As

Publication number Publication date
US8778402B2 (en) 2014-07-15
IL233784A0 (en) 2014-09-30
PT2806855T (pt) 2018-09-28
MX2014008631A (es) 2014-08-21
RS57637B1 (sr) 2018-11-30
EP3527196B1 (en) 2022-09-07
DK3527199T3 (da) 2022-10-24
ES2683254T3 (es) 2018-09-25
TW201334810A (zh) 2013-09-01
EA026267B1 (ru) 2017-03-31
ES2929807T3 (es) 2022-12-01
MA35859B1 (fr) 2014-12-01
MX368199B (es) 2019-09-24
CN104080444A (zh) 2014-10-01
DK3527196T3 (da) 2022-10-24
KR101786586B1 (ko) 2017-10-18
HUE040525T2 (hu) 2019-03-28
TN2014000322A1 (en) 2015-12-21
LT3527199T (lt) 2022-12-12
EP3527199A1 (en) 2019-08-21
PH12014501565A1 (en) 2014-10-08
EP3527197B1 (en) 2022-09-07
US10946029B2 (en) 2021-03-16
RS63952B1 (sr) 2023-02-28
MY165888A (en) 2018-05-18
KR101895279B1 (ko) 2018-09-05
WO2013110632A1 (en) 2013-08-01
HRP20221433T1 (hr) 2023-01-06
EP3527198B1 (en) 2024-10-09
LT3527197T (lt) 2022-11-25
PL3412277T3 (pl) 2023-06-19
RS63759B1 (sr) 2022-12-30
FI3412277T3 (fi) 2023-03-23
US20150164915A1 (en) 2015-06-18
CN105726548B (zh) 2019-05-14
SG11201404350PA (en) 2014-08-28
CY1120684T1 (el) 2019-12-11
HUE060705T2 (hu) 2023-04-28
EP3020394A1 (en) 2016-05-18
CN104080444B (zh) 2017-06-20
US10028964B2 (en) 2018-07-24
CL2014001966A1 (es) 2014-11-14
EP3527198A1 (en) 2019-08-21
CN105726548A (zh) 2016-07-06
HRP20221432T1 (hr) 2023-01-06
DK3412277T3 (da) 2023-02-20
ES2928688T3 (es) 2022-11-22
NZ627837A (en) 2016-04-29
PL2806855T3 (pl) 2018-12-31
HRP20221431T1 (hr) 2023-01-06
TWI559940B (en) 2016-12-01
KR20150089093A (ko) 2015-08-04
DK3527197T3 (da) 2022-10-24
PT3527197T (pt) 2022-10-26
BR112014017481A2 (pt) 2017-06-13
HUE061566T2 (hu) 2023-07-28
US20130189324A1 (en) 2013-07-25
AU2013211656B2 (en) 2017-07-13
LT2806855T (lt) 2018-10-10
PE20141703A1 (es) 2014-11-24
RS63706B1 (sr) 2022-11-30
EA201690187A1 (ru) 2016-05-31
CA2862548C (en) 2020-07-07
UA115543C2 (uk) 2017-11-27
RS63761B1 (sr) 2022-12-30
KR101560288B1 (ko) 2015-10-14
GEP201706767B (en) 2017-11-10
HUE060421T2 (hu) 2023-02-28
KR20140114374A (ko) 2014-09-26
EP3412277A1 (en) 2018-12-12
AR089805A1 (es) 2014-09-17
BR112014017481A8 (pt) 2021-06-15
ES2929137T3 (es) 2022-11-25
EP3527197A1 (en) 2019-08-21
EA031566B1 (ru) 2019-01-31
HRP20181550T1 (hr) 2018-11-30
US20180296573A1 (en) 2018-10-18
EP3527199B1 (en) 2022-09-07
DK2806855T3 (en) 2018-09-03
LT3527196T (lt) 2022-11-25
ZA201405464B (en) 2015-12-23
HK1200021A1 (en) 2015-07-31
HUE060402T2 (hu) 2023-02-28
HRP20230147T1 (hr) 2023-03-31
PT3527199T (pt) 2022-11-08
PH12014501565B1 (en) 2014-10-08
PT3527196T (pt) 2022-10-18
PT3412277T (pt) 2023-02-14
EP2806855A1 (en) 2014-12-03
LT3412277T (lt) 2023-04-25
PL3527197T3 (pl) 2022-11-21
SI3412277T1 (sl) 2023-03-31
AU2013211656A1 (en) 2014-07-24
CA2862548A1 (en) 2013-08-01
PL3527196T3 (pl) 2022-11-21
EP3527196A1 (en) 2019-08-21
CO7010836A2 (es) 2014-07-31
KR20170116234A (ko) 2017-10-18
ES2938466T3 (es) 2023-04-11
JP2015508416A (ja) 2015-03-19
EA201491281A1 (ru) 2014-12-30
PL3527199T3 (pl) 2022-12-12
EP2806855B1 (en) 2018-07-11
JP6104282B2 (ja) 2017-03-29
SI2806855T1 (sl) 2018-11-30
EP3412277B1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
WO2014007781A3 (en) Inhalation compositions
WO2014007771A3 (en) Inhalation compositions comprising muscarinic receptor antagonist
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
PT2617451T (pt) Conjunto para administrar um medicamento e inalador de dose única para a administração de um medicamento em pó que tenha esse conjunto

Legal Events

Date Code Title Description
FG Grant or registration